DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hereditary multiple exostoses — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary multiple exostoses maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary multiple exostoses is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
exostosin glycosyltransferase 1 (EXT1) — EXT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet udpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7SCK · 2.8 Å · ligand URIDINE-5'-DIPHOSPHATE (UDP). Experimental structure, not a prediction.
What the evidence adds up to
Hereditary multiple exostoses is a rare autosomal dominant skeletal disorder characterised by multiple osteochondromas, mostly diagnosed in childhood. The condition can present with a wide spectrum of severity, from asymptomatic to skeletal deformities or neurovascular complications. Pain and swelling are often the first symptoms that lead a patient to seek medical attention. Complications include joint deformity, fractures through the tumour pedicle, mechanical block of nearby joints, nerve compression, and malignant change. One case report describes a seventeen-year-old male with hereditary multiple exostoses who presented with foot drop due to common peroneal nerve palsy.
No medical treatment is currently available for hereditary multiple exostoses. Lesions can be removed with surgical excision if there is aesthetic concern or complications such as deformities or, rarely, malignant transformation. The management of nerve compression complications, such as foot drop, is discussed in the literature in terms of a physiatric approach, but no drug therapy is described.
A 1949 study of four members of a Negro family with the condition intended to include total protein, dextrose tolerance, calcium, phosphorus and other hormonal excretion studies, but those investigations were not completed due to circumstances beyond the authors' control. No further biochemical or pharmacological data from that study are available.
What is still missing is any proven medical or pharmacological treatment for hereditary multiple exostoses. No drug has been tested in a clinical trial for this condition. There is no data on patient stratification by genetic mutation or disease severity that could guide future therapy. Funding for basic research into the molecular pathways of osteochondroma formation and for clinical trials of potential repurposed drugs remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Journal of Pain · 2011 · 9 citations
Bisphosphonates for Pain Management in Children With Benign Cartilage Tumors
AbstractOBJECTIVES: Cochrane meta-analyses have shown significant benefit in bone pain from bisphosphonate therapy in adults with bone diseases such as multiple myeloma, Paget disease, breast and prostate cancer. Our aim was to assess if bisphosphonate treatment could alleviate severe pain in children with Ollier disease and hereditary multiple exostoses that are refractory to standard analgesics. METHODS: We report our clinical experience with bisphosphonate therapy in 2 children with cartilage tumors, one with Ollier disease, and the other with hereditary multiple exostoses. RESULTS: We found bisphosphonate therapy to be helpful for pain relief and improving overall ability to carry out daily activities. DISCUSSION: One can consider bisphosphonate therapy in children with Ollier disease and hereditary multiple exostoses who have debilitating pain that is refractory to standard analgesic treatment.
New England Journal of Medicine · 1949 · 1 citations
Hereditary Multiple Exostoses
AbstractHEREDITARY multiple exostoses are a distinct clinical entity more frequently encountered than is generally appreciated.We have recently had the opportunity of studying 4 members of a Negro family who had the condition. Few cases occurring in Negroes are reported in the American literature.1 2 3 To our knowledge this is the first Negro family studied and reported.The cases were typical in both the clinical and roentgenologic aspects, varying, of course, in degree. It was our intention originally to include total protein, dextrose tolerance, calcium, phosphorus and other hormonal excretion studies in the investigation. Owing to circumstances beyond our control it . . .
Eurasian Journal of Family Medicine · 2021 · 0 citations · open access
A Family with Hereditary Multiple Exostoses
AbstractHereditary multiple exostoses is a rare autosomal dominant genetic disorder characterized by multiple exostoses (osteochondromas), mostly diagnosed in childhood. It may manifest with a wide spectrum from asymptomatic to skeletal deformities or neurovascular complications. Pain and/or swelling are often the first symptoms for patients to consult a doctor. Although no medical treatment is currently available, lesions can be removed with surgical excision in case of aesthetic anxiety or complications such as deformities or rarely, malign transformation. In this article, three individuals from the same family with hereditary multiple exostoses are described who were evaluated within the core competencies of family medicine. Keywords: exostoses, multiple hereditary, osteochondroma, scoliosis
Journal of Shaheed Suhrawardy Medical College · 2012 · 0 citations · open access
Hereditary Multiple Exostoses Complicated By Common Peroneal Nerve Palsy
AbstractHereditary multiple exostoses is an autosomal dominant skeletal disorder. It is characterized by multiple bony prominences and skeletal deformities. It can lead to a series of complications including deformity of the joint, fractures through the tumor pedicle, mechanical block of nearby joints, nerve compression and malignant change. In this case it has been described a rare case of a seventeen-year old male patient with a history of hereditary multiple exostoses presented with foot drop. The management and Physiatric approach are discussed. DOI: http://dx.doi.org/10.3329/jssmc.v4i1.12001 J Shaheed Suhrawardy Med Coll, 2012;4(1):32-34
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
